(UroToday.com) Relugolix is a novel oral LHRH agonist, compared to the LHRH agonist degarelix which had to be injected. Degarelix is associated with high rates of injection site-reaction. Recently, the FDA approved relugolix, an oral GnRH antagonist, for the treatment of advanced prostate cancer patients.